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the chi-square test CONCLUSIONS: Despite the fact that clusters are generated
from different approaches and have no similar characteristics, a plausible corre-
spondence seems to develop between them. Thus, our investigations may help in
identifying countless promising market strategies facilitating the access of new
drugs according to UK regional standards.
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DETERMINANTS OF HEALTH SERVICE UTILIZATION IN URBAN PAKISTAN
Jahangeer RA
Pakistan Institute of Development Economics (PIDE), Islamabad, Pakistan
OBJECTIVES: To examine inequalities in health service utilisation in urban Paki-
stan. This analysis investigates how household economic status, duration of illness
and distance to a provider influence health service utilisation in Pakistan.
METHODS: The study uses data from the Pakistan Socioeconomic Survey (PSES)
and analysis is based on 1,407 individuals who belong to 855 urban households.
Health care providers are classified into public hospitals, other public providers,
private doctors/clinics and other private providers. Household economic status is
measured by a wealth index constructed using data from the survey on ownership
of durable assets and housing conditions. Principal components analysis (PCA) is
used to construct the index. Multinomial logistic regression is used to investigate
the effects of various characteristics of individuals/households on health service
utilisation in Pakistan. RESULTS:Overall, 79.6% of those reporting any health com-
plaint sought health care. A large gap in health service utilisation exists between
poorest patients (60.5%) and richest patients (84.9%). Almost three-fourth patients
visited private providers; 57.3% visited private doctors/clinics and 15.7% visited
other private providers. The remaining one-fourth patients visited public providers
(19.7% visited public hospitals and 7.2% other public providers). Multinomial logis-
tic regression reveals that poorest patients are significantly more likely (p0.10) to
visit public hospitals whereas patients of poorest, poor, middle and rich house-
holds are significantly less likely to visit private doctors/clinics compared to mem-
bers of richest households controlling for other factors such as education, occupa-
tion, duration of illness, distance to a provider and residence. An additional day of
illness significantly (p0.01) increases the likelihood of visiting public hospitals
and private doctors/clinics. The distance travelled to visit a provider shows a sig-
nificant positive (p0.01) and negative association with visiting public hospitals
and other private providers respectively. CONCLUSIONS: Large gaps exist in health
service utilization in urban Pakistan.
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OBJECTIVES: Generate preliminary estimates of active health care professional
(HCP) time required /potential time and cost savings between SC vs. IV rituximab
processes at the care unit and pharmacy in sites participating in T&M sub-study to
MO25455 trial (ClinicalTrials.gov identifier NCT01461928). METHODS: As part of an
ongoing multi-country, multi-centre, prospective, T&M study run as a sub-study to
MO25455, one interview with a nurse and pharmacy member was conducted per
site, using a structured questionnaire to elicit practice pattern flow and time esti-
mates for rituximab-related tasks for both IV and SC processes. Estimates of SC
injection time were obtained from the Spark-Thera Phase Ib trial (BP22333) (in the
absence of staff-elicited time estimates). Estimated total time/cost was calculated
as the sum of individual task times/costs. UK salary costs were assumed. Results
were pooled and descriptive statistics were calculated. RESULTS:Median total HCP
time for IV vs. SC processes was estimated at 57 and 26 minutes, respectively,
equivalent to approximately £79 and £37 (estimated 54% reduction with SC). For IV,
process time is taken up by premedication (27%) and rituximab pharmacy recon-
stitution (18%), with the remaining 55% distributed across other care unit tasks. For
SC, premedication (57%), injection (24%) and rituximab pharmacy dispensing (19%)
constitute the whole process. Potential time savings are expected because of avoid-
ing tasks related mainly to infusion line (dis)connection, infusion initiation/dose
escalations, and IV pharmacy reconstitution, which is only partially being replaced
by SC injection. CONCLUSIONS: A switch from IV to SC rituximab potentially re-
sults in important care unit and pharmacy time savings to be reinvested in improv-
ing overall patient care. Patients could potentially be moved out of the chemother-
apy care unit to receive SC administration in other settings and free up valuable
chair time, thereby increasing the unit’s throughput and overall efficiency. Data of
the T&M study is awaited.
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OBJECTIVES: To compile pharmaceutical expenditure in Greece by financing
scheme and type of provider, in order to investigate areas that cost containment
measures could be monitored effectively. METHODS: The method used for the
estimation of pharmaceutical expenditure is based on the System of Health Ac-
counts 2011 set by OECD, EUROSTAT, and WHO, taking into consideration the
national needs for data reporting both in outpatient and inpatient settings. Data
were reported by type of provider, including hospital pharmacies, Social Security
Funds (SSF) pharmacies, private pharmacies and local authorities social pharma-
cies as well as by financing schemes, including SSFs, private payments and NHS
payments. Additionally, pharmaceutical data are analysed using the new interna-
tional classification of Factors of Health Care Provision. Estimates were obtained
for 2009 & 2010. RESULTS: Total pharmaceutical expenditure-TPE (outpatient &
inpatient) in Greece, decreased by 9,3% between 2009 & 2010. Pharmaceutical out-
patient expenditure covered by SSF was estimated at €5.1 bl for 2009 (2.2% of GDP)
and €4.46 bl for 2010 (2% of GDP). Less than 8% of outpatient pharmaceutical ex-
penses covered by SSF, concern pharmaceuticals dispensed by NHS & SSF pharma-
cies. These public pharmacies dispense expensive pharmaceuticals (for serious
and chronic diseases) at significantly lower prices than private pharmacies. Inpa-
tient pharmaceutical expenses decreased by 9,1% (€1.2 bl in 2009 and €1.1 bl in
2010), representing 15.3% of total pharmaceutical expenditures (outpatient and
inpatient), a proportion similar to the mean of other EU countries estimated at
about 17%. Measures to control the volume of consumption were recently intro-
duced via e-prescribing and the set up of controlling mechanisms. CONCLUSIONS:
Reductions in pharmaceutical expenditure are correlated mainly to price reduc-
tions and less to a decrease in volume of consumption. Measures concerning phar-
maceutical cost containment have to be reorganised not only concerning price and
volume but also concerning new –innovative ways of distributing pharmaceuticals.
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OBJECTIVES: We provide an estimate of public expenditures on cancer prevention
in Alberta. Our estimate covers all three levels of government – federal, provincial,
and municipal. METHODS: Public cancer prevention is a government activity
whose purpose is to expressly reduce the future incidence of cancer. As part of
a wider initiative, we conducted a survey of ministries, in search of all programs
whose express purpose was to promote health and prevent illness. We searched
web pages, ministry annual reports and federal and provincial budget papers. We
collected data on program type, type of intervention, and program cost. We then
verified the results with each ministry. We sorted the data by risk factors, and
selected those risk factors that were related to cancer. RESULTS: Expenditures for
those risk factors that are related to cancer are shown in Table 1. In total expendi-
tures on these risk factors were $206. Of this, about two-thirds were expenditures
that were incurred by non-health, provincial ministries. The risk factor with the
highest preventive expenditures was environmental health. CONCLUSIONS: In
Alberta, all levels of government spent $206 per person on risk factors that can
prevent cancer, mostly in the long run. Without a cost – effectiveness analysis, we
cannot say that this amount is too much or too little. However with this data, and
a cost effectiveness analysis, we can in fact say whether we are spending too much
or too little.
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A POPULATION-BASED STUDY OF THE RESOURCE UTILIZATION AND COSTS OF
TREATING RESECTABLE NON-SMALL CELL LUNG CANCER
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OBJECTIVES: To describe resource utilization and costs associated with treating
surgically managed non-small-cell lung cancer (NSCLC) patients in Ontario, Can-
ada; to compare characteristics and average costs of patients treated with adjuvant
therapy to surgery alone; and to compare resource utilization and costs across
health care regions. METHODS: A population-based retrospective cohort study of
surgically resected NSCLC patients, diagnosed from Ontario Cancer Registry be-
tween 2004 and 2006, was identified using administrative health care data. Patients
were followed for four years from date of surgery (to represent the cohort imme-
diately affected by the change in clinical practice -- recommended adjuvant cispla-
tin-based treatment). Cost estimates (2001 CAN dollars) were derived from admin-
istrative data and the literature. RESULTS: Patients who received adjuvant
chemotherapy in addition to surgery were younger and had a less severe burden of
co-morbid disease than patients treated with surgery alone (p0.001). Geographic
variation was found with respect to age, Charlson score, and socioeconomic status.
Rates of chemotherapy, the proportion of patients who received any imaging
scans, hospitalizations, specialist visits, emergency room visits, mean number of
imaging scans, general physician visits, and blood transfusions all varied signifi-
cantly among geographic regions. The average cost of a patient treated with sur-
gery and adjuvant chemotherapy was $36,617.70 and was significantly higher than
the average cost of a patient treated with surgery alone ($29,071.60) (p0.0001).
Among regions, the average cost of patients treated with chemotherapy was sim-
ilar, while the average cost of patients treated with surgery alone varied signifi-
cantly (p0.0008). CONCLUSIONS: Differences exist in the average cost of treating
a resectable NSCLC patient with surgery and adjuvant chemotherapy in compari-
son with surgery alone. This phase IV population-based study demonstrates a
similar cost per patient as evidenced in the randomized controlled trials. Under-
standing why these patients incur higher average costs is important with respect to
delivering cost-effective treatment.
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OBJECTIVES: To calculate direct medical costs of diabetes and its complications for
insulin users from the perspective of the health insurance fund. METHODS: A
6-month, prospective, observational bottom-up cost study of diabetes type 1 and
type 2 for patients on insulin or combined insulin plus oral anti-diabetic therapy
was performed. Data were gathered for anti-diabetic drugs, concomitant medi-
cines, medical devices and hospitalizations, due to diabetes and its complications.
Official drug prices were taken from the positive drug list. All other costs were
gathered from the national framework contract. The annual cost per patient was
calculated for the year 2011 (1.95 BGN 1 EUR). RESULTS: A total of 430 (254 type 2)
patients were included into the study. The total cost per patient per year is BGN
4.500. Out of them, 57% are hospitalization costs due to polyneuropathy, glaucoma,
retinopathy, nephropathy, amputations, and diabetic angiopathy. Anti-diabetic
medicines account for 23% of all costs, medical devices for 4%, and outpatient
treatment of complications and concomitant diseases for 16%. Statistically signif-
icant differences are observed in the cost structure between country regions with
the highest cost per patient in the capital. The percentage of anti-diabetic medi-
cines in the total cost varies depending on the age group: 31% for 20-44 year olds,
29% for 45-59 year olds and 19% for diabetics above 60 years. On the opposite, the
hospitalization cost due to diabetes and its complications is 61% in the oldest age
group while in the youngest is 44%. CONCLUSIONS: Our study confirms that dia-
betes is a costly disease and the majority of the total health care costs relate to
treatment of diabetes complications.
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OBJECTIVES: The Japanese government has recently been promoting home-care.
Local community pharmacies have been playing an important role in home-care,
but virtually no research has been done to clarify the exact nature of their activities.
This study was therefore conducted to elucidate the prescription infrastructure
and home visit activities being conducted by community pharmacies. METHODS:
In March 2012, questionnaires were mailed to community pharmacies in two cities
in Osaka prefecture. The principal items surveyed were the background character-
istics of the patients receiving home visit, the number of pharmacists working at
the pharmacies, and the pharmacies’ facilities/equipment. RESULTS: We received
responses from 90 of the 201 community pharmacies surveyed (response rate:
44.8%). Of these 90 pharmacies, 44 performed home visit. The patients visited at
home were 79.7 years old, on average; 31.8% lived alone, and 22.7% lived with a
spouse, with no children in the home. The responding pharmacies had an average
of 2.2 full-time and 2.5 part-time pharmacists on staff. The mean number of pre-
scriptions filled per day was 80.5, and 91.1% of the pharmacies did not possess
sterile compounding equipment. Of the responding pharmacies, 83.1% stocked
narcotic drugs, and the mean number of narcotics drugs stocked was 8.7. The
parameters that were found to be correlated to the performance of home visit were
the number of full-time pharmacists [p  0.003], the number of narcotic drugs
stocked [p  0.060], and the number of medical instruments/materials possessed
[p  0.057]. CONCLUSIONS: The results show that the patients being visited by
pharmacists are more likely to be elderly living alone who need their drug use
managed by a pharmacist. Most pharmacies conducting home visit do not have
sterile compounding equipment, half of the pharmacists working at these phar-
macies are part-time, and not all of these pharmacies necessarily stock narcotic
drugs.
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OBJECTIVES: To estimate the ICU drug cost impact of clinical pharmacists’ inter-
ventions at the Ghent University Hospital. METHODS: A patient cohort with phar-
macist intervention (I) was compared with a control group (M) (Jan 08 – Dec 11).
Matching criteria were admission year, hospital length of stay (LOS), All Patient
Refined Diagnosis Related Group (APR-DRG), Major Diagnostic Category (MDC),
mortality rate, age. Generic drug names, selected from a pharmacists’ ICU - inter-
vention database were included in the analysis if the cost/daily defined dose
(WHO.int) multiplied with the intervention rate was  50€: acetaminophen, acy-
clovir, ceftazidim, enoxaparin, erythromycin, (es)omeprazole, fluconazole, levo-
floxacin, linezolid, meropenem, piperacillin tazobactam, ranitidin, somatostatin,
teicoplanin, vancomycin, (val)ganciclovir, voriconazole. The average ICU drug cost
was compared between groups and a “drug cost per number of used units” ratio
was calculated: lower ratio for (I) was considered as a more efficient use. (Data are
in % or median with interquartile range IQR; statistical analysis in SPSS, Chi Square
Test; p0.05). RESULTS: Eighty-nine ICU patients receiving intervention were
matched with 167 patients. Median LOS was respectively 39 (22 – 72) days for (I) and
35 (20 – 71) (M). Mortality rate was 29% (both groups). Most prevalent APR-DRG was
septicemia: 16.9% (I); 18.6% (M). Average ICU drug cost was 346.75€ (I) compared to
397.64€ (M) (p0.001); for the selected drugs 168.23€ (I) and 144.52€ (M) (not signif-
icant). Ratios in favour of (I) were found for ceftazidime (p0.001), meropenem
(p0.001), piperacillin tazobactam (p0.001) and teicoplanin (p0.001).
CONCLUSIONS: Average ICU drug cost was lower in a group of patients receiving
pharmacist interventions but this trend could not be attributed to the 19 most
costly and prevalent drugs in intervention. However, for 4 of these drugs data
suggest a more efficient use. This finding needs to be confirmed with prospective
data and to be balanced with health outcomes.
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HOW DO PHARMACISTS ADVISE DIABETES PATIENT SELF-MANAGEMENT
DURING THE HOLY MONTH OF RAMADAN?
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OBJECTIVES: Many diabetes patients choose to participate in the Ramadan fast
despite medical and religious advice to the contrary. Pharmacists are accessible
health care resources whose guidance can help ensure safe fasting in these indi-
viduals. The aim of this study is to describe Qatar pharmacists’ current practice,
knowledge, and attitudes towards diabetes medication management during
Ramadan.METHODS:A cross-sectional survey was administered to a convenience
sample of 500 pharmacists practicing in Qatar. The 30-item questionnaire was
systematically developed following comprehensive literature review. The volume
and nature of pharmacist interactions with diabetes patients were explored, as
were attitudes regarding pharmacist roles in diabetes care during Ramadan.
Awareness and access of relevant resources was assessed and knowledge of spe-
cific therapeutic and dosing recommendations was evaluated according to the
proposed diabetes medication management and patient risk-assessment strate-
gies endorsed by international medical and religious bodies. RESULTS: The survey
was completed by 166 (33%) pharmacists during May and June 2012. Eighty-eight
(53%) were based in ambulatory care and reported somewhat more interaction (at
least weekly) with diabetes patients during Ramadan than hospital pharmacists
(70.4%, vs. 55.8%, p0.08). Three-quarter of respondents had never read recom-
mended diabetes Ramadan guidelines with 62% using internet resources as their
primary reference to answer fasting-related diabetes questions. Two-thirds of re-
spondents correctly identified how to modify oral diabetes therapy dosing during
Ramadan, but just 20 (12%) did so for insulin. Despite stated barriers of workload,
insufficient access to patient medical records and private counseling areas, phar-
macists overwhelmingly expressed willingness to assume greater roles in diabetes
patient education during Ramadan. CONCLUSIONS: Qatar pharmacists frequently
interact with diabetes patients, but application of recommended medical guide-
lines for care and medication dosing for fasting patients is not optimal. Despite
barriers limiting enhanced participation in diabetes patient management during
Ramadan, pharmacists are interested in developing these services.
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OBJECTIVES: The concept of allocation of research funding in health care depend-
ing on the disease-specific burden to the society was proposed by the governmen-
tal institutions in the USA and Europe. Unfortunately, recent data from the USA
showed that this concept has been unsuccessfully implemented. The objective was
to perform a systematic review of allocation of research funding in health care in
Europe. METHODS: We performed a systematic review of all publications, which
investigated the allocation of research funding in health care of different European
countries in the last 10 years (234 hits). In Germany, we interviewed the main state
funding institutions to acquire data on allocation of funding in national health
care. Data on funding allocation were compared with disability-adjusted life years
(DALY), prevalence and costs of diseases. RESULTS: Data on funding allocation are
not available for the most European countries. Disease burden was inadequately
reflected in those countries where data were available. A comparison between
cancer, coronary heart disease, dementia and stroke, which are among the most
common causes of mortality and disability in Europe, revealed that cancer receives
over 70% of total research funding. Although the health-economic burden of de-
mentia and cancer is similar, dementia receives approximately 10 times less fund-
ing. In the UK, Switzerland and Denmark, cancer receives 49.175€, 25.162€ and
24.424€ of funding per one million of costs. The research funding per one million of
costs is substantially lower in dementia (2.145€ in UK, 11.300€ in Switzerland und
6.808€ in Denmark), and stroke (4.693€, 15.000€ and 11.788€, respectively).
CONCLUSIONS: Disease burden is still inadequately reflected in allocation of re-
search funding in Europe. There is an underfunding of research in brain diseases,
such as stroke and dementia, which are associated with substantial economic
burden. Health-political solutions are necessary to improve the implementation of
the research funding concept.
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HBA1C TEST UTILIZATION AMONG HOSPITALIZED PATIENTS WITH
HYPERGLYCEMIA
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OBJECTIVES: To evaluate the utilization of and factors associated with HbA1c test-
ing in the inpatient setting among patients with hyperglycemia. METHODS: Data
were obtained from Humedica’s Integrated Delivery Networks from October 1, 2009
through September 30, 2011. The analyses focused on hospitalization episodes
(admissions and observations) among pre-diabetic/undiagnosed and diabetic pa-
tients with blood glucose values 140 mg/dl, and are descriptive in nature. Results
are statistically significant at the p0.05 level unless otherwise noted. RESULTS: A
total of 55,614 patients contributed to 94,638 unique hospitalization episodes with
at least one occurrence of hyperglycemia. HbA1c tests were performed in 24.6% of
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